there is no big money in this stock. just a bunch of market makers and their friendly shorts in short pants scared to death
not so (moreover revenues are growing @30%/yr--any vending machine companies doing that kind of growth?):
On Track Innovations Ltd. designs, develops, and markets cashless payment solutions. The company operates through three segments: Retail and Mass Transit, Petroleum, and Parking. Its products include WAVE that provides contactless payment and security capabilities to iPhone and Android mobile devices; WAVE PKI, a device-agnostic add-on for audio jacks of smartphones, tablets, and personal computers; oti Payment Insert, a bridge to contactless payment for MasterCard, Visa and other card associations, debit and credit, e-Purse, mass transit ticketing, e-coupons, and loyalty programs; near-field communication (NFC) and contactless reader solutions to payments point-of-sale providers; and oti Saturn 6500, a NFC and contactless reader.
more likely that they get bought out by Google at $20. You know they want those mobile payments and the ad revenue that will fly in when they share actual buying habits of customers with advertisers
not likely, but AAPL and USPS have very different customer bases. as pay by phone tech becomes cheaper in future yrs and can be incorporated into low end phones, then UEPS and its customers may in time benefit from such infrastructure
i have never seen a stock trade on level 2 with such odd lots. both trade and bid/asks are weird odd lots more often then not.
right you are, i was obviously conflating the base number with the proposed target ($10) and not the actual base ($6)
well... $10 seems reasonable, certainly in the pre-market following notice of approval. that's 40% from here. then there is upside for market share based on safety profile vs competition. and there are always calls for one concerned limiting and defining losses in a case the case of non appoval, but given the active drugs in this one are already
FDA approved, and the trials show both safety and efficacy, approval seems highly likely on this go-round.
Up to $805 million in direct payments from Abbvie to INFI: $275 upfront for rights and an additional $530 million in milestone payments. Following any duvelisib FDA approvals: a co-commercialization of the drug and an even 50/50 split of US profits ( somewhere between 24% and 31% profit sharing for INFI outside US) Abbive and INFI will spilt the costs trials. (INFI's R&D is running under $30 million/quarter at present.
...you're going to love INFI in late 2014 and 2015:
you're going to love INFI in late 2014 through 2015. Check out RBC analyst Michael Yee's comments on the INFI / Abbvie partnership in the online article posted by Investor's Business Daily.
as for listening to some "fraudulet idiot," yes, that is sound advise; but only facts can determine who that person is. Is it you?
Egotistical voicings such as "we longs gonna win this won (sic) soon. 12 and beyond" are the sort of emotional investment that generally results in substantial losses when the tape starts to trick against one's egotistical bias.
So, on this "great website": what is the commission cost for executing a trade? Is it only Chinese stocks that the subscriber can trade? What is the minimum amount of money necessary to open a trading account?
I'm just curious to know from one who has enough Chinese to visit the platform, navigate it, and report back on such common particulars as these.
yep, a company making an assessment such as seeking alpha or citron should have access to a Chinese speaker who could check it out: including commission on trades that Citron claims it can't find and other such details. That is obvious, so why all the debate when facts should be easy to check for any Chinese speaker?
No, you completely agree with me. I was clearly being facetious. My point Is your point: "Like putting gasoline on a fire."
it is my kindest hope for the shorts that they are adding more to their positions at these levels. FCEL has no future, and no large company is interested in buying it. buy leveraging on this short opportunity shorts will be able to cover FCEL at prices twice as high as at present. that is how to play the future---short it and then say how fortunate you were wrong.
bench and human factor....this is cheap to fix..... looking for shorts and marker makers to take it down as far as possible, watch the tape ready to buy